register

News & Trends - MedTech & Diagnostics

Smith+Nephew launches new unicompartmental knee system

Health Industry Hub | May 25, 2020 |

MedTech News: Smith+Nephew announces the launch of its new JOURNEY II Unicompartmental Knee (UK) System. Built on the heritage of one of the most clinically successful partial knees and paired with proprietary OXINIUM™ Technology, JOURNEY II UK is designed to help patients rediscover their normal life.

JOURNEY II UK provides a highly personalised approach to partial knee arthroplasty, via a modular, two-tray configuration, which may drive value and cost reduction in sterilisation costs through a reduced OR footprint and instrumentation that can be customised to match a familiar surgical flow.

Through the introduction of a lateral-specific tibia baseplate and an increased size range for femoral components and medial tibia baseplates, the JOURNEY II UK System provides a unique opportunity to optimise bone coverage in both the medial and lateral compartments of the knee.

Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“The updated instrumentation presented by the JOURNEY II Unicompartmental Knee System, paired with the increased range in implant sizes and a lateral specific baseplate, makes it easy to reproducibly perform well-balanced medial and lateral unicompartmental arthroplasties,” said Dr. Tad Gerlinger, Midwest Orthopaedics at Rush University Medical Centre, Chicago, IL.

Unicompartmental procedures may result in a reduction of cost to payers, via decreased implant and procedure costs, compared to total knee arthroplasty. When paired with Smith+Nephew’s innovative enabling technologies, the JOURNEY II UK’s two-tray footprint is reduced and may offer healthcare providers increased value in a comprehensive solution to unicompartmental knee procedures.

“Our JOURNEY II Unicompartmental Knee System brings a much-needed solution to the partial knee space. Our customers want it because partial knees enable faster recovery and improved functionality for their patients,” said Skip Kiil, President of Orthopaedics at Smith+Nephew. “Adding to these benefits, JOURNEY II UK is also designed to deliver high patient satisfaction.” 

Smith+Nephew’s JOURNEY II UK System is now available in North America and Europe for partial knee applications.

In alignment with the Government’s mental health initiative the #SelfcareInHealthcare campaign has been launched to support Pharma, Biotech and MedTech industry professionals. The initiative is supported by Medicines Australia, AusBiotech, MTAA and ARCS Australia. Learn more.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.